Zobrazeno 1 - 10
of 3 078
pro vyhledávání: '"Nonsmall-cell lung cancer"'
Publikováno v:
Shipin yu jixie, Vol 40, Iss 3, Pp 149-155 (2024)
Objective: To explore the effects of Brassica rapa L. acid polysaccharide 1 (BRAP-1) on H226 cell tumor-bearing mice. Methods: 60 mice were divided into the model group (0.1 mL/10 g), positive cisplatin [3 mg/(kg·2 d)], BRAP-1 low dose [50 mg/(kg·d
Externí odkaz:
https://doaj.org/article/f9ed71b8234d4ebe88d56841ee2558fa
Publikováno v:
Radiology Case Reports, Vol 19, Iss 4, Pp 1528-1532 (2024)
Percutaneous lung ablation is increasingly used in the treatment of lung malignancies with good outcomes, but recurrence is commonly reported in ablation of lesions size larger than 3 cm. We report a 50-year-old female with a 9 cm nonsmall cell lung
Externí odkaz:
https://doaj.org/article/bf7a1fdf06b847588e464cc57c13c41c
Autor:
Kyoko Sumiyoshi, Hiroshi Yatsushige, Keigo Shigeta, Yuuki Aizawa, Asuka Fujino, Nozomi Ishijima, Takanori Hayakawa
Publikováno v:
Heliyon, Vol 10, Iss 18, Pp e38128- (2024)
Purpose: Although the treatment of nonsmall cell lung cancer (NSCLC) has rapidly progressed recently, there is little evidence of treatment for patients with symptomatic brain metastases (BM) and poor performance status (PS). However, in symptomatic
Externí odkaz:
https://doaj.org/article/92fa68011b244f42aafc5115e47ece18
Autor:
Hai‐jun Dong, Cheng‐yan Yang
Publikováno v:
The Clinical Respiratory Journal, Vol 18, Iss 5, Pp n/a-n/a (2024)
Abstract Introduction This meta‐analysis sought to investigate the effect of neoadjuvant chemotherapy (NACT) combined with surgery in patients with nonsmall cell lung cancer (NSCLC). Methods With time span from January 2010 to December 2022, PubMed
Externí odkaz:
https://doaj.org/article/0f55bbfcaa68402d8337a9d9ec38722f
Autor:
Xiang Zhao, Yuan Cheng, Cuiyan Guo, Ligong Nie, Qi Zhang, Meng Zhang, Kunyan Sun, Guangfa Wang
Publikováno v:
Health Science Reports, Vol 7, Iss 5, Pp n/a-n/a (2024)
Abstract Background and Aims Immune checkpoint inhibitors (ICIs) across multiple treatment lines have not yet been evaluated comprehensively. The purpose of this research was to investigate whether or not continuous cross‐line ICIs therapy is effec
Externí odkaz:
https://doaj.org/article/c0356fab5fb94e639e0fe17f24d8cc4e
Autor:
Shuji Murakami, Kanako Shinada, Yuka Otsutsumi, Fumiko Komine, Yuan Yuan, Junko Nakamura, Seigo Katakura, Tetsuro Kondo, Terufumi Kato, Tomoyuki Yokose, Haruhiro Saito
Publikováno v:
Cancer Medicine, Vol 13, Iss 7, Pp n/a-n/a (2024)
Abstract Purpose Genetic mutation detection has become an important step in nonsmall‐cell lung cancer (NSCLC) treatment because of the increasing number of drugs that target genomic rearrangements. A multiplex test that can detect multiple gene mut
Externí odkaz:
https://doaj.org/article/1402e9a4128a4aaf8f054c648279390c
Autor:
Jun Sugisaka, Yukihiro Toi, Yosuke Kawashima, Yutaka Domeki, Tomoiki Aiba, Sachiko Kawana, Atsushi Nakamura, Shinsuke Yamanda, Yuichiro Kimura, Shunichi Sugawara
Publikováno v:
Thoracic Cancer, Vol 14, Iss 31, Pp 3140-3146 (2023)
Abstract Background There is no well‐established late‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC). Therefore, we retrospectively determined the efficacy and safety of platinum rechallenge with paclitaxel‐carbopl
Externí odkaz:
https://doaj.org/article/84ab70da4dee413d96eac46f9b6875a9
Publikováno v:
Forum of Clinical Oncology, Vol 13, Iss 3, Pp 3-14 (2023)
Tumoral heterogeneity has been associated with treatment resistance and failure in patients with cancer. Tumoral heterogeneity can be either intertumoral (static variation of cancer cells) or intratumoral (spatial and temporal variation of cancer cel
Externí odkaz:
https://doaj.org/article/2c19c4f0752f4321ac4343dd4181e745
Publikováno v:
The Clinical Respiratory Journal, Vol 18, Iss 1, Pp n/a-n/a (2024)
Abstract Introduction Regulator of G protein signalling 1 (RGS1) closely regulates malignant phenotypes and tumour immunity in several cancers, while its clinical value in nonsmall cell lung cancer (NSCLC) is by far rarely reported. Consequently, thi
Externí odkaz:
https://doaj.org/article/817d33239d51491d9c2e4348dd864d2d
Publikováno v:
Health Science Reports, Vol 6, Iss 11, Pp n/a-n/a (2023)
Abstract Background and Aims Nonsmall cell lung cancer accounts for over 85% of lung cancer incidences worldwide, and often has a poor prognosis. Proteasome inhibitors, such as bortezomib, have previously demonstrated evidence in preclinical and clin
Externí odkaz:
https://doaj.org/article/f7df0a84ac2744dfb45a61f51b1e5754